FDA approval for Medtronic tissue heart valve:
This article was originally published in Clinica
The US FDA has granted marketing approval for Medtronic's Mosaic porcine tissue heart valve. The device is a reduced-profile valve incorporating a flexible stent. It incorporates two Medtronic proprietary technologies: alpha-amino oleic acid treatment and the physiological fixation process. The company intends to delay launching the product until later this year due to "unprecedented demand" for its existing tissue valve range. Meantime it is increasing valve production to meet demand.
You may also be interested in...
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.